Lower Injection–Related HIV–1 Risk Associated With Participation in a Harm Reduction Program in Kazan, Russia

2007 ◽  
Vol 19 (1) ◽  
pp. 13-23 ◽  
Author(s):  
Larissa Badrieva ◽  
Eugeny Karchevsky ◽  
Kevin S. Irwin ◽  
Robert Heimer
Keyword(s):  
Harm Reduction ◽  
Harm Reduction Program ◽  
Reduction Program ◽  
Hiv 1

scholarly journals Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Abdolhalim Rajabi ◽  
Heidar Sharafi ◽  
Seyed Moayed Alavian
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Harm Reduction ◽  
People Who Inject Drugs ◽  
Linear Trend ◽  
Meta Analysis ◽  
Harm Reduction Program ◽  
Pooled Prevalence ◽  
Reduction Program ◽  
Before And After

Abstract Background Prevalence of hepatitis C virus (HCV) infection among people who inject drugs (PWID) in Iran is high. Since 2005, the Iranian government has implemented a harm reduction program to control HCV. We aimed to describe the prevalence of HCV antibody (Ab) in Iranian PWID before and after the implementation of harm reduction with cumulative meta-analysis. Methods Following PRISMA guidelines, we conducted a systematic review and meta-analysis of studies published on the seroprevalence of HCV among PWID. We systematically reviewed the literature to identify eligible studies up to December 2018 in international and national databases. Pooled prevalence and 95% confidence intervals were calculated using Der Simonian and Laird method, taking into account conceptual heterogeneity. Subgroup analyses were performed by harm reduction implementation and studies’ characteristics to assess the sources of heterogeneity. We used Cochran–Armitage test for the linear trend of the prevalence of HCV Ab among PWID. Results We reviewed 5966 papers and reports and extracted data from 62 eligible records. The pooled HCV Ab prevalence among PWID in Iran was 46.5% (95% confidence interval [95% CI] 41.1–52.0%). Overall, the Cochran–Armitage test for trend indicated a significant decreasing trend of HCV Ab prevalence (P = 0.04). The cumulative meta-analysis showed a slight decline in the prevalence of HCV Ab between the years 2005 and 2018. Conclusions The HCV Ab prevalence among PWID in Iran is high, with a considerable geographical variation. The prevalence of HCV Ab among PWID in Iran slightly decreased after 2005 which could be, at least to some extent, related to the implementation of extensive harm reduction programs in the country.

Possibilities of implementing harm reduction program for smokers. Current status and recommendations

2019 ◽  
Vol 11 (3-4) ◽  
pp. 41-50
Author(s):  
Bartosz Łoza ◽  
Karina Jahnz-Różyk ◽  
Dorota Karkowska ◽  
Wojciech Kozubski ◽  
Artur Mamcarz ◽  
...  
Keyword(s):  
Harm Reduction ◽  
Current Status ◽  
Harm Reduction Program ◽  
Reduction Program

Harm reduction programs the opportunity for psychiatric and substance use treatment

2011 ◽  
Vol 26 (S2) ◽  
pp. 79-79
Author(s):  
N. Martínez-Luna
Keyword(s):  
Substance Use ◽  
Harm Reduction ◽  
Psychiatric Treatment ◽  
Methadone Maintenance ◽  
Substance Use Treatment ◽  
Harm Reduction Program ◽  
Reduction Program ◽  
Methadone Maintenance Program ◽  
Drug Problems ◽  
Outpatient Drug

IntroductionAt least one-half of patients in substance use treatment have been diagnosed with comorbid psychiatric disorders. High prevalence of severe mental disorders co-occurring with substance use have been described. Harm reduction refers to policies, programs and practices that aim to reduce the harms associated with the use of illegal drugs in people unable or unwilling to stop.ObjectivesTo describe attendance and integration of patients with substance use disorders in a harm reduction program, to psychiatric treatment.AimsFind the importance and profitability of Harm Reduction Programs as an access door to psychiatric treatment in people with drug addiction.MethodsData was gathered from the first interview survey made to patients that contacted the Harm Reduction Program or attending the Outpatient Drug Clinic Vall d’Hebron in Barcelona between January 2005 until September 2010.ResultsA total of 348 patients (males = 71%, European community origin = 92%, mean age = 28,18 years). 63,8% of patients were under medical and psychiatric treatments, 55,4% attended the Methadone Maintenance Program, 7,4% other psychiatric treatments, and other treatments without specification 30,7%. The residential status was: 38% squatters, homeless 9,7%, hostel 3,4%, home 43%, lodging 2%, others 3%.ConclusionsMore than fifty percent of harm reduction program patient's were in a psychiatric treatment, it is an advantage that in the outpatient drug clinic of Vall d’Hebron both programs are included: harm reduction and psychiatric assessment. Access to integral treatment is important for people with drug problems, but many people with drug problems are unable or unwilling to get treatments.

Psychotic Symptoms of Cocaine Self-Injectors in a Harm Reduction Program

2013 ◽  
Vol 34 (2) ◽  
pp. 118-121 ◽  
Author(s):  
Carlos Roncero ◽  
Nieves Martínez-Luna ◽  
Constanza Daigre ◽  
Lara Grau-López ◽  
Begoña Gonzalvo ◽  
...  
Keyword(s):  
Harm Reduction ◽  
Psychotic Symptoms ◽  
Harm Reduction Program ◽  
Reduction Program
Sign in / Sign up

Export Citation Format

Share Document